Oncocross Co., Ltd. (KOSDAQ:382150)

Oncocross Statistics

Total Valuation

Oncocross has a market cap or net worth of KRW 115.18 billion. The enterprise value is 93.49 billion.

Market Cap	115.18B
Enterprise Value	93.49B

Important Dates

The next estimated earnings date is Friday, March 20, 2026.

Earnings Date	Mar 20, 2026
Ex-Dividend Date	n/a

Share Statistics

Oncocross has 12.11 million shares outstanding. The number of shares has increased by 15.16% in one year.

Current Share Class	12.11M
Shares Outstanding	12.11M
Shares Change (YoY)	+15.16%
Shares Change (QoQ)	+0.79%
Owned by Insiders (%)	25.08%
Owned by Institutions (%)	10.95%
Float	6.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	130.20
PB Ratio	7.23
P/TBV Ratio	7.25
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-11.22
EV / Sales	105.68
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.77

Financial Position

The company has a current ratio of 9.43, with a Debt / Equity ratio of 0.32.

Current Ratio	9.43
Quick Ratio	9.18
Debt / Equity	0.32
Debt / EBITDA	n/a
Debt / FCF	-0.53
Interest Coverage	-41.58

Financial Efficiency

Return on equity (ROE) is -58.44% and return on invested capital (ROIC) is -33.23%.

Return on Equity (ROE)	-58.44%
Return on Assets (ROA)	-24.60%
Return on Invested Capital (ROIC)	-33.23%
Return on Capital Employed (ROCE)	-31.38%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +29.74% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+29.74%
50-Day Moving Average	10,588.00
200-Day Moving Average	10,766.40
Relative Strength Index (RSI)	48.92
Average Volume (20 Days)	184,291

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncocross had revenue of KRW 884.68 million and -8.33 billion in losses. Loss per share was -716.67.

Revenue	884.68M
Gross Profit	657.23M
Operating Income	-8.99B
Pretax Income	-8.33B
Net Income	-8.33B
EBITDA	-8.38B
EBIT	-8.99B
Loss Per Share	-716.67

Balance Sheet

The company has 26.77 billion in cash and 5.08 billion in debt, with a net cash position of 21.69 billion or 1,791.07 per share.

Cash & Cash Equivalents	26.77B
Total Debt	5.08B
Net Cash	21.69B
Net Cash Per Share	1,791.07
Equity (Book Value)	15.94B
Book Value Per Share	1,325.95
Working Capital	24.69B

Cash Flow

In the last 12 months, operating cash flow was -6.89 billion and capital expenditures -2.68 billion, giving a free cash flow of -9.57 billion.

Operating Cash Flow	-6.89B
Capital Expenditures	-2.68B
Free Cash Flow	-9.57B
FCF Per Share	-789.96

Margins

Gross Margin	74.29%
Operating Margin	-1,016.38%
Pretax Margin	-942.14%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncocross does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.16%
Shareholder Yield	-15.16%
Earnings Yield	-7.24%
FCF Yield	-8.31%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Oncocross has an Altman Z-Score of 2.47 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.47
Piotroski F-Score	3